Psychedelics
'A wild west': Patients seek new depression treatments with different mechanisms of action
Patients have become increasingly disillusioned with traditional depression treatments, and the search for new therapies has created some chaos in the field, according to experts.
VIDEO: One dose of LSD improved generalized anxiety disorder up to 12 weeks
NEW YORK — One dose of lysergide produced clinical remission of generalized anxiety disorder as soon as 4 weeks after treatment, according to a study presented at the American Psychiatric Association annual meeting.
Patent granted for first new forms of MDMA, clearing path to a potential FDA approval
Terran Biosciences has been awarded a U.S. patent for the world’s first new salts and polymorphs of MDMA, pharmaceutical compositions using these forms, and the method of use for treatment of PTSD, according to a company press release.
Beckley Psytech reports positive results in trial of treatment-resistant depression drug
More than half of patients with treatment-resistant depression achieved response with a single dose of BPL-003, a benzoate salt formulation of 5-MeO-DMT that is administered intranasally, according to a press release from the manufacturer.
Link between psychedelic use, manic symptoms in teens may be associated with genetics
While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.
FDA grants priority review to MDMA-assisted therapy for PTSD
The FDA has accepted and granted priority review to a new drug application for midomafetamine capsules used in combination with psychological intervention for PTSD, according to a press release from Lykos Therapeutics.
Top psych stories of 2023: Physician burnout, ‘transformative’ psychedelics, more
Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.
'A Promethean moment': Psychedelics could be prescribed in the next few years
With potential FDA approvals on the horizon, the controversy surrounding psychedelics in clinical practice may soon reach a tipping point, according to experts.
Psychedelics have ‘potential to be transformative’ in saving health care system millions
Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.
First patient dosed in study of synthetic psychedelic for treatment-resistant depression
Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.